Age-specific Incidence of Breast Cancer Subtypes: Understanding the Black-white Crossover
Overview
Authors
Affiliations
Background: Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). We used newly available population-based data to examine whether the age-specific incidences of breast cancer subtypes vary by race and ethnicity.
Methods: We classified 91908 invasive breast cancers diagnosed in California between January 1, 2006, and December 31, 2009, by subtype based on tumor expression of estrogen receptor (ER) and progesterone receptor (PR)-together referred to as hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2). Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR(+)/HER2(-)), ER or PR positive and HER2 positive (HR(+)/HER2(+)), ER and PR negative and HER2 positive (HR(-)/HER2(+)), and ER, PR, and HER2 negative (triple-negative). We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). All P values are two-sided.
Results: We did not observe an age-related black-white crossover in incidence for any molecular subtype of breast cancer. Compared with white women, black women had statistically significantly higher rates of triple-negative breast cancer at all ages but statistically significantly lower rates of HR(+)/HER2(-) breast cancers after age 35 years (all P < .05). The age-specific incidence of HR(+)/HER2(+) and HR(-)/HER2(+) subtypes did not vary markedly between white and black women.
Conclusions: The black-white crossover in breast cancer incidence occurs only when all breast cancer subtypes are combined and relates largely to higher rates of triple-negative breast cancers and lower rates of HR(+)/HER2(-) breast cancers in black vs white women.
Liu Y, Li Y, Zhu Y, Wang M, Luan Z Discov Oncol. 2024; 15(1):631.
PMID: 39514138 PMC: 11549074. DOI: 10.1007/s12672-024-01522-y.
Wong M, Jones V, Yu W, Bosserman L, Lavasani S, Patel N Cancer Med. 2024; 13(16):e70096.
PMID: 39157928 PMC: 11331244. DOI: 10.1002/cam4.70096.
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center.
Podany E, Bulsara S, Sanchez K, Otte K, Ellis M, Kinik M NPJ Breast Cancer. 2024; 10(1):70.
PMID: 39097576 PMC: 11297908. DOI: 10.1038/s41523-024-00672-0.
Xu L, Liddell B, Nesic K, Geissler F, Ashwood L, Wakefield M NAR Cancer. 2024; 6(3):zcae033.
PMID: 39055334 PMC: 11270467. DOI: 10.1093/narcan/zcae033.
Is STARD3 A New Biomarker for Breast Cancer?.
Korucu A, Inandiklioglu N Eur J Breast Health. 2024; 20(2):89-93.
PMID: 38571685 PMC: 10985577. DOI: 10.4274/ejbh.galenos.2024.2024-1-7.